- cafead Dec 14, 2023 at 09:42: AM
via After a year of layoffs and declining share prices in the wake of a late-stage clinical failure, Rain Oncology’s search for a suitable buyer has paid off.
AI-focused Pathos AI will pay $1.16 per share of Rain, which Pathos described as a 17% premium on Rain’s share price on Oct. 13. In addition, Rain’s shareholders can also expect a contingent value right for up to an additional 17 cents per share depending on the company’s final finances.
article source
AI-focused Pathos AI will pay $1.16 per share of Rain, which Pathos described as a 17% premium on Rain’s share price on Oct. 13. In addition, Rain’s shareholders can also expect a contingent value right for up to an additional 17 cents per share depending on the company’s final finances.
article source